120 巻 (2010) 2 号 p. 163-171
Anti-TNFα (tumor necrosis factor-α) agents, adalimumab and infliximab, are the first biologics approved for the treatment of psoriasis in Japan. Although these agents are expected to have remarkable effects on psoriasis and/or psoriatic arthritis, and to improve QOL (quality of life) of patients with psoriasis, there is growing concern regarding the potential serious adverse reactions such as infections including tuberculosis as well as bacterial and Pneumocystis pneumonia. The guideline and safety manual have been developed to ensure that anti-TNFα agents are properly used by board-certified dermatologists experienced in practice of psoriasis. Requirements for physicians and medical institutions, eligible patients for treatment with anti-TNFα agents, dosage and administration of each anti-TNFα agents, general considerations for administration, contraindications, safety precautions for high-risk patients for adverse reactions, and recommendable combination therapies with anti-TNFα agents are referred.